Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Atai Life Sciences 第四季度和 2023 年全年业绩：现金流急剧流失但2026年的目标依然存在，Psychedelic Pipeline 的最新消息
Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:ATAI) announced its consolidated financial results for the fourth quarter and full year 2023.
临床阶段的迷幻药生物技术公司Atai Life Sciences（纳斯达克股票代码：ATAI）公布了其第四季度和2023年全年的合并财务业绩。
The Numbers:
数字：
Cash, cash equivalents and short-term investments of $154.2 million by December 31, 2023, as compared to $273.1 million by December 31, 2022.
Quarterly and full-year R&D expenses of $14.2 million and $62.2 million, respectively, as compared to $21.9 million and $74.3 million for the same periods in 2022.
Quarterly and full-year General and Administrative (G&A) expenses of $19.4 million and $63.6 million, respectively, as compared to $15.7 million and $70.4 million in the same periods in 2022.
Quarterly and full-year net loss of $18.3 million and...
截至2023年12月31日，现金、现金等价物和短期投资为1.542亿美元，而截至2022年12月31日为2.731亿美元。
季度和全年研发费用分别为1,...
登录免费看全文
登录/注册